Ligand Pharmaceuticals Incorporated (LGND)
Nasdaq: LGND · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 1994
Grade6.3
◀ Past 5.7● Present 6.9▶ Future 6.0
Who owns Ligand Pharmaceuticals Incorporated
As filed with the SECHolders of 5% or more
5
Blackrock, Inc. holds 14.5% of Common Stock, as its SCHEDULE 13G/A filed Oct 17, 2025 says.
Directors and officers
10
report now, of 18 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Oct 17, 2025 · Common Stock · 15.6% in Feb 5, 2025
Invesco LTD
SCHEDULE 13G · filed Aug 13, 2026 · Common Stock
Vanguard Portfolio Management
SCHEDULE 13G · filed May 1, 2026 · Common Stock
Janus Henderson Group PLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock · 5.5% in Aug 14, 2025
Vanguard Capital Management
SCHEDULE 13G · filed May 1, 2026 · Common Stock
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What LGND reports owning in othersstakes of 5% or more, and other ties
Pelthos Therapeutics Inc. PTHS
SCHEDULE 13D/A · filed Nov 10, 2025 · Common Stock, par value $0.0001 per share
Xoma Royalty Corporation
SCHEDULE 13D · filed May 1, 2026 · Common Stock, par value $0.0075 per share
Other ties the annual report names
Inv IOs
An investee · investee · invested in, named in the 10-K filed Feb 27, 2026
InvIOs Holding AG
An investee · investee · invested in, named in the 10-K filed Feb 27, 2026
Orchestra BioMed
An investee · investee · invested in, named in the 10-K filed Feb 27, 2026
Pelthos Technologies
An investee · investee · invested in, named in the 10-K filed Feb 27, 2026
Primrose Bio
An investee · investee · invested in, named in the 10-K filed Feb 27, 2026
Vikings
An investee · investee · invested in, named in the 10-K filed Feb 27, 2026
Novan, Inc.
A company bought · acquisition · Dec 2023 · owns, named in the 10-K filed Feb 27, 2026
Apeiron
A company bought · acquisition · owns, named in the 10-K filed Feb 27, 2026
11 subsidiaries in 3 countries, from the list filed with the 10-K filed Feb 27, 2026.
Insider tradesForm 4
149sales
0purchases
121sales on a scheduled plan
8people selling
$35.7Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window8 of 20 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Espinoza Octavio | Chief Financial Officer | 14 | $13.0M | 13 | 0 | $0 |
| Reardon Andrew | CLO & Secretary | 73 | $11.9M | 73 | 0 | $0 |
| Haas Jason | director | 3 | $3.7M | 0 | 0 | $0 |
| Aryeh Jason | director | 15 | $3.0M | 0 | 0 | $0 |
| Lamattina John L | director | 5 | $1.6M | 0 | 0 | $0 |
| Sabba Stephen L | director | 3 | $1.2M | 0 | 0 | $0 |
| Kozarich John W | director | 35 | $1.0M | 35 | 0 | $0 |
| Zimmermann Martine | director | 1 | $300,000 | 0 | 0 | $0 |